甲状腺乳头状癌颈部淋巴结转移的研究进展

doi:10.3969/j.issn.1007-9572.2016.36.026

摘要/Abstract

摘要： 临床上颈部淋巴结转移是甲状腺乳头状癌（PTC）最主要的转移途径，转移顺序通常是由中央区转移至颈侧区，其发病隐匿，诊断较困难，手术方案的选择尚未统一，本文就PTC颈部淋巴结转移的一般规律、高危因素、诊断、治疗及预后等情况作一个综述，期望为临床筛选PTC颈部淋巴结转移高危患者、确定合理的治疗方案提供帮助。

关键词: 甲状腺肿瘤, 淋巴转移, 颈淋巴结清扫术

Abstract: Cervical lymph node metastasis is the main transfer pathway of papillary thyroid carcinoma （PTC）,the transfer order is usually from the central zone to lateral area.The diagnosis is difficult because of its occult onset,and the surgical scheme has not yet unified.Here we reviewed general rules,risk factors,diagnosis,treatment and prognosis of cervical lymph node metastasis in PTC,in order to help clinic screen high-risk patients with cervical lymph node metastasis of PTC and determine the reasonable treatment options.

Key words: Thyroid neoplasms, Lymphatic metastasis, Neck dissection

侯文群, 杨小敏. 甲状腺乳头状癌颈部淋巴结转移的研究进展[J]. 中国全科医学, 2016, 19(36): 4533-4536.

HOU Wen-qun, YANG Xiao-min. Research Progress of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma[J]. Chinese General Practice, 2016, 19(36): 4533-4536.

参考文献

［1］SHAH J P，PATEL S G.头颈外科学与肿瘤学［M］. 韩德民,于振坤，译.3版.北京：北京人民卫生出版社,2005：5,355. SHAH J P，PATEL S G. Head and neck surgery and oncology［M］.HAN D M，YU Z K，translate. Beijing：Beijing People's Medical Publishing House,2005：5,355. ［2］ZETOUNE T,KEUTGEN X,BUITRAGO D,et al.Prophylactic central neck dissection and local recurrence in papillary thyroid cancer:a meta-analysis［J］.Ann Surg Oncol,2010,17（12）:3287-3293. ［3］LANG B H,NG S H,LAU L,et al.A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy［J］.Thyroid，2013,23（9）:1087-1098. ［4］STOPA M,BARCZYNSKI M,KONTUREK A,et al.Prevalence of metastatic lymph nodes in the central compartment of the neck following prophylactic clearance for papillary thyroid cancer［J］.Przegl Lek,2011,68（12）:1166-1169. ［5］BIAN X,CHEN H,YE X,et al.Role of level VI lymph nodes metastasis in cervical metastasis of patients with papillary thyroid cancer［J］.Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi，2010,45（8）:664-668. ［6］LAI V,YEN T W,ROSE B T,et al.The effect of thyroiditis on the yield of central compartment lymph nodes in patients with papillary thyroid cancer［J］.Ann Surg Oncol,2015,22（13）:4181-4186. ［7］CHENG S P,LIU C L,HSU Y C,et al.Expression and biologic significance of diponectin receptors in papillary thyroid carcinoma［J］.Cell Biochem Biophys,2013,65（2）:203-210. ［8］LEE Y S,LIM Y S,LEE J C,et al.Nodal status of central lymph nodes as a negative prognostic factor for papillary thyroid carcinoma［J］.J Surg Oncol,2013,107（7）:777-782. ［9］PARK C H,SONG C M,JI Y B,et al.Significance of the extracapsular spread of metastatic lymph nodes in papillary thyroid carcinoma［J］.Clin Exp Otorhinolaryngol,2015,8（3）:289-294. ［10］CHEN Q,RAGHAVAN P,MUKHERJEE S,et al.Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer［J］.Radiol Med,2015,120（10）:959-966. ［11］CAMPENNI A,VIOLI M A,RUGGERI R M,et al.Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid ancer［J］.Nucl Med Commun,2010,31（4）:274-279. ［12］ERBIL Y,SARI S,AGCAOGLU O,et al.Radio-guided excision of metastatic lymph nodes in thyroid carcinoma:a safe technique for previously operated neck compartments［J］.World J Surg，2010,34（11）:2581-2588. ［13］GILES Y S,SARICI I S,TUNCA F,et al.The rate of operative success achieved with radioguided occult lesion localization and intraoperative ultrasonography in patients with recurrent papillary thyroid cancer［J］.Surgery,2014,156（5）:1116-1126. ［14］KACZKA K,FENDLER W,BOROWIEC M,et al.First one-step nucleic acid amplification testing in papillary thyroid cancer lymph nodes——a comparison with histopathology and real-time PCR［J］.Endokrynol Pol,2014,65（6）:422-430. ［15］LIU X,OUYANG D,LI H,et al.Papillary thyroid cancer:dual-energy spectral CT quantitative parameters for preoperative diagnosis of metastasis to the cervical lymph nodes［J］.Radiology,2015,275（1）:167-176. ［16］LIU Y,XU Y,LIU Y,et al.Detection of cervical metastatic lymph nodes in papillary thyroid carcinoma by Fourier transform infrared spectroscopy［J］.Br J Surg,2011,98（3）:380-384. ［17］LIU Y Q,GAO M J,XU Y Z,et al.Investigation on Fourier transform infrared spectrum of metastatic lymph node in thyroid cancer［J］.Guang Pu Xue Yu Guang Pu Fen Xi,2009,29（11）:2917-2921. ［18］SOHN Y M,KIM M J,KIM E K,et al.Diagnostic performance of thyroglobulin value in indeterminate range in fine needle aspiration washout fluid from lymph nodes of thyroid cancer［J］.Yonsei Med J,2012,53（1）:126-131. ［19］TUMINO S,BELFIORE A.Appearance of antithyroglobulin antibodies as the sole sign of metastatic lymph nodes in a patient operated on for papillary thyroid cancer:a case report［J］.Thyroid,2000,10（5）:431-433. ［20］ZHANG H S,WANG R J,FU Q F,et al.Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer［J］.Asian Pac J Cancer Prev,2014,15（24）:10905-10909. ［21］MIKOSINSKI S,POMORSKI L,SZUKOWSKA L,et al.The diagnostic value of thyroglobulin concentration in fine-needle aspiration of the cervical lymph nodes in patients with differentiated thyroid cancer［J］.Endokrynol Pol,2006,57（4）:392-395. ［22］SCHERL S,MEHRA S,CLAIN J,et al.The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes:what are we missing when we don’t perform a prophylactic dissection of central compartment lymph nodes in papillary thyroid cancer? ［J］.Thyroid,2014,24（8）:1282-1288. ［23］VANNUCCHI G,COVELLI D,PERRINO M,et al.Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes［J］.Endocrine,2014,47（2）:648-651. ［24］STACK BC J R,FERRIS R L,GOLDENBERG D,et al.American Thyroid Association consensus review and statement regarding the anatomy,terminology,and rationale for lateral neck dissection in differentiated thyroid cancer［J］.Thyroid,2012,22（5）:501-508. ［25］American Thyroid Association （ATA） Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,COOPER D S,DOHERTY G M,et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2009,19（11）:1167-1214. ［26］HARTL D M,LEBOULLEUX S,AL GHUZLAN A,et al.Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma［J］.Ann Surg,2012,255（4）:777-783. ［27］PERROS P,BOELAERT K,COLLEY S,et al.Guidelines for the management of thyroid cancer［J］.Clin Endocrinol（Oxf）,2014,81（Suppl 1）:1-122. ［28］MOO T A,MCGILL J,ALLENDORF J,et al.Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma［J］.2010,34（6）:1187-1191. ［29］CALO P G,MEDAS F,PISANO G,et al.Differentiated thyroid cancer:indications and extent of central neck dissection-our experience［J］.Int J Surg Oncol,2013:625193.DOI:10.1155/2013/625193.Epub 2013 Sep 26. ［30］HOLOSTENCO V,KHAFIF A.The upper limits of central neck dissection［J］.JAMA Otolaryngol Head Neck Surg,2014,140（8）:731-735. ［31］KAMEYAMA K,TAKAMI H.Lymph node micrometastases of thyroid cancer［J］.Nihon Geka Gakkai Zasshi,2013,114（1）:34-37. ［32］KIKUMORI T,IMAI T.Our surgical strategy for thyroid carcinoma［J］.Nihon Rinsho,2007,65（11）:2029-2034. ［33］MACDONALD K I,TAYLOR S M,CAVANAGH J,et al.Level VI node size as a predictor of malignancy in papillary thyroid cancer［J］.J Otolaryngol Head Neck Surg,2010,39（2）:136-141. ［34］ZUNIGA S,SANABRIA A.Prophylactic central neck dissection in stage N0 papillary thyroid carcinoma［J］.Arch Otolaryngol Head Neck Surg,2009,135（11）:1087-1091. ［35］PAPINI E,BIZZARRI G,BIANCHINI A,et al.Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer［J］.J Clin Endocrinol Metab,2013,98（1）:E92-97. ［36］LEE J,SONG Y,SOH E Y.Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence［J］.World J Surg,2014,38（4）:858-862. ［37］PARK Y M,WANG S G,LEE J C,et al.Metastatic lymph node status in the central compartment of papillary thyroid carcinoma:a prognostic factor of locoregional recurrence［J］.Head Neck,2016,38 （Suppl 1）:E1172-1176. ［38］PARK Y M,WANG S G,SHIN D H,et al.Lymph node status of lateral neck compartment in patients with N1b papillary thyroid carcinoma［J］.Acta Otolaryngol,2016,136（3）:319-324. ［39］SCHNEIDER D F,CHEN H,SIPPEL R S.Impact of lymph node ratio on survival in papillary thyroid cancer［J］.Ann Surg Oncol,2013,20（6）:1906-1911. ［40］URKEN M L.Management of well-differentiated thyroid cancer in 2010:perspectives of a head and neck surgical oncologist［J］.Endocr Pract,2010,16（5）:903-912. ［41］URKEN M L,HASER G C,IKHTEROV I,et al.The impact of metastatic lymph nodes on risk stratification in differentiated thyroid cancer:have we reached a higher level of understanding? ［J］.Thyroid,2016,26（4）:481-488.

[1]	白鑫, 武新宇, 赵尊, 柳舒心, 刘斯淼, 薛宇航, 徐俊玲, 高永举. ¹³¹I治疗血清甲状腺球蛋白抗体阳性分化型甲状腺癌远处转移的疗效研究[J]. 中国全科医学, 2024, 27(15): 1833-1837.
[2]	张继方, 陈芳, 唐佳雯, 李红亮. 肿瘤出芽及肿瘤浸润淋巴细胞对食管鳞状细胞癌淋巴结转移的预测价值研究[J]. 中国全科医学, 2023, 26(32): 4038-4042.
[3]	赵泽玮, 康宁, 郭丰丽, 王钟玉, 郑向前. 极光激酶A表达对甲状腺髓样癌切除术后患者生化治愈的影响作用研究[J]. 中国全科医学, 2023, 26(20): 2508-2512.
[4]	欧阳向柳, 高蓓, 王艳滨, 刘丽云, 顾程, 郑立春. 原发性甲状腺淋巴瘤的超声特征研究[J]. 中国全科医学, 2022, 25(15): 1869-1874.
[5]	孙磊，李梅. 促甲状腺激素抑制治疗可能影响骨骼健康，分化型甲状腺癌该如何科学管理？[J]. 中国全科医学, 2021, 24(8): 941-946.
[6]	马丹，尹新博，刘佳惠，方群垚，何秋，熊钰，龚放华. 不同药物干预方案对131I辅助治疗甲状腺癌患者唾液腺功能保护作用的网状Meta分析[J]. 中国全科医学, 2021, 24(30): 3828-3836.
[7]	谢兴伟，刘春梅，刘书仙，申航，张道龙，钟丽萍，孔令伟. 基于“生物-心理-社会”模式的甲状腺癌术后患者一例报道及全科诊疗思路[J]. 中国全科医学, 2020, 23(5): 623-628.
[8]	高凤娟，赵洁，韩琤琤，刘菊红，何志宏，温秀芹，谢妍，张鸣，姚军，叶京明. 一例分化型甲状腺癌患者健康管理全科医生教学案例分析[J]. 中国全科医学, 2020, 23(32): 4141-4145.
[9]	何宇，杨汐，燕红，王帅奇. 治疗前刺激性甲状腺球蛋白、刺激性甲状腺球蛋白和甲状腺球蛋白减少指数对分化型甲状腺癌患者131I治疗后长期缓解的预测价值研究[J]. 中国全科医学, 2020, 23(30): 3798-3805.
[10]	刘述欢，田浩明，李舍予. 促甲状腺素抑制治疗分化型甲状腺癌的安全性研究进展[J]. 中国全科医学, 2020, 23(11): 1333-1337.
[11]	方超，吴婷婷，周莹颖，薛珺，杨伟伟. 超声联合诊断甲状腺乳头状癌颈淋巴结转移的应用价值[J]. 中国全科医学, 2019, 22(24): 3000-3004.
[12]	季新强，孙俊勇，刘晶. 北京大学肿瘤医院1996—2015年甲状腺癌手术患者临床病理资料回顾性研究[J]. 中国全科医学, 2018, 21(27): 3360-3365.
[13]	李斐，李舍予. 全球甲状腺癌疾病负担[J]. 中国全科医学, 2018, 21(26): 3155-3159.
[14]	郎然，金建军，张彭辉，边静. 紫杉醇治疗甲状腺未分化癌的安全性和有效性研究[J]. 中国全科医学, 2018, 21(24): 2932-2936.
[15]	南润玲，尚培中*，张伟，朱习琴. 原发性甲状腺淋巴瘤二例分析并文献复习[J]. 中国全科医学, 2017, 20(6): 747-750.